NCT07182149View on ClinicalTrials.gov

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

May 30, 2027

Study Completion Date

October 31, 2028

Conditions
HNSCCESCCEsophageal AdenocarcinomaGastric AdenocarcinomaGEJ AdenocarcinomaOvarian CancerNSCLCCervical CancerEndometrial Cancer
Interventions
DRUG

NRM-823

NRM-823 is a bispecific T-Cell Engager

All Listed Sponsors
lead

Normunity AccelCo, Inc.

INDUSTRY